Supernus Pharmaceuticals, Inc.
SUPN
$50.53
$1.162.35%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 38.63% | 21.48% | 9.34% | -1.71% | 4.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 38.63% | 21.48% | 9.34% | -1.71% | 4.30% |
| Cost of Revenue | 47.17% | -7.14% | 3.67% | -6.08% | 161.76% |
| Gross Profit | 35.23% | 34.61% | 11.39% | -1.19% | -15.86% |
| SG&A Expenses | 34.27% | 52.48% | 36.58% | 10.07% | 9.05% |
| Depreciation & Amortization | 29.61% | 34.43% | 24.82% | 3.54% | -1.74% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.19% | 29.24% | 24.61% | 2.80% | 6.04% |
| Operating Income | -6.36% | -39.81% | -70.08% | -38.83% | -64.69% |
| Income Before Tax | -2.04% | -107.25% | -228.95% | -36.62% | -2,499.59% |
| Income Tax Expenses | -160.99% | -80.18% | -299.15% | -191.29% | 4,938.66% |
| Earnings from Continuing Operations | 80.61% | -126.78% | -217.20% | 12.97% | -9,637.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 80.61% | -126.78% | -217.20% | 12.97% | -9,637.90% |
| EBIT | -6.36% | -39.81% | -70.08% | -38.83% | -64.69% |
| EBITDA | 39.62% | -4.21% | -31.28% | -16.52% | -18.87% |
| EPS Basic | 81.20% | -125.90% | -214.30% | 10.88% | -9,304.35% |
| Normalized Basic EPS | -90.28% | -43.89% | -67.67% | -29.94% | -196.91% |
| EPS Diluted | 81.11% | -126.71% | -215.94% | 11.11% | -9,722.73% |
| Normalized Diluted EPS | -90.28% | -42.87% | -67.16% | -29.77% | -200.00% |
| Average Basic Shares Outstanding | 3.19% | 3.39% | 2.54% | 1.90% | 1.94% |
| Average Diluted Shares Outstanding | 3.19% | 1.56% | 0.96% | 1.65% | 0.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |